Figure 1.
Using multivariable analysis adjusted for known clinical prognostic factors and receipt of bevacizumab, baseline serum albumin (b-alb) remained a significant independent predictor of (Top) overall survival (OS) (P =.0009) and (Bottom) time to disease progression (TTP) (P =.04). ULN indicates upper limit of normal; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazards ratio; 95% CI, 95% confidence interval.